USA flag logo/image

An Official Website of the United States Government

ELIMINATION OF ANTIGEN REACTIVE B CELLS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
7897
Program Year/Program:
1988 / SBIR
Agency Tracking Number:
7897
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Medarex, Inc.
707 State Road Princeton, NJ 08540
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1988
Title: ELIMINATION OF ANTIGEN REACTIVE B CELLS
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

MEDAREX HAS EXCLUSIVE LICENSE TO SEVERAL MONOCLONAL ANTIBODIES (MABS) REACTIVE TO THE HIGH AFFINITY FC RECEPTOR FOR IGG (FCGRI), ON HUMAN MONOCYTES. THIS RECEPTOR IS A CRITICAL TRIGGER MOLECULE FOR ADCC BY THESE CELLS AND HAS BEEN SHOWN TO MEDIATE KILLING OF RED CELL TARGETS AND TUMOR LIKE CELLS. WE PROPOSE TO DETERMINE THE FEASIBILITY OF USING THESE REAGENTS TO ELIMINATE ANTIGEN REACTIVE B CELLS. STUDIES BY CONSULTANTS TO MEDAREX INDICATE THAT THIS APPROACH PERMITS LYSIS OF B CELL-LIKE TARGETS (HYBRIDOMA CELLS EXPRESSING SURFACE IG). WE NOW PROPOSE TO DEMONSTRATETHAT NORMAL B CELLS REACTIVE TO PARTICULAR ANTIGENS CAN BE KILLED IN A SIMILAR FASHION. OUR SPECIFIC AIMS ARE, THEREFORE, TO INVESTIGATE, USING AN IN VITRO MOUSE MODEL SYSTEM, WHETHER OUR ANTI-FCGRI MABS, WHEN COUPLED TO ANTIGEN (TNP) CAN 1) MEDIATE KILLING OF RESTING ANTIGEN REACTIVE B CELLS BY HUMAN MONOCYTES; 2) TARGET HUMAN MONOCYTES TO ELIMINATE ANTIGEN REACTIVE B CELLS; AND 3) MEDIATE ELIMINATION OF PLAQUE FORMING CELLS.

Principal Investigator:


0

Business Contact:

Small Business Information at Submission:

Medarex Inc
1401 Broad St Clifton, NJ 07015

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No